Merger to result in NYSE American-listed company focused on developing therapeutics based on Serina’s proprietary POZ Platform™ delivery technology Lead program of the combined company will be SER-252 (POZ-apomorphine) for the...
PITTSBURGH, April 11, 2023 /PRNewswire/ -- LyGenesis, Inc., a clinical-stage biotechnology company developing allogenic cell therapies for large unmet needs, and Imagine Pharma, a biotechnology company focused on the development of its novel polypeptide (IMG-1)...
LONDON--(BUSINESS WIRE)--Relation Therapeutics, a leader in the use of high-resolution biology, machine learning and clinical insights to discover life-changing medicines, announced today the opening of their flagship integrated wet–dry laboratory....
February 15, 2023 - Boston, MA – Morphoceuticals Inc., a biotechnology company, announced it closed an $8 million Seed-2 funding round led by Prime Movers Lab and initial investor Juvenescence....
Our co-founder, Greg Bailey, discusses what's next for AgeX, investing in longevity now, Cognitive Switch relaunch, and importance of prevention.
Our co-founder, Greg Bailey, talks with Jess Larsen of the Innovation and Leadership podcast, about groundbreaking breakthroughs in anti-aging research that could revolutionize how we view aging.
Our CEO, Richard Marshall talks with Longevity Technology about Juvenescence’s mission, pipeline and where he sees future potential.
On the Dealmakers Show Bailey talks about the problem with taking VC money, biotech investing, ketosis, and essential supplements for living longer.
![[Conference] Hevolution | The Global Roadmap for Healthy Longevity: Enabling Longer, Healthier Lives in the Gulf](http://juvlabs.com/cdn/shop/files/Greg_Conf_Photo.jpg?v=1678116964&width=550)
February 19, 2023 | Saudi Arabia
Dr. Greg Bailey was part of a panel of Healthy Longevity Innovators who spoke about their work and opportunities in the space and how they see the road evolving. Panel starts at 5:28.00.
![[Conference] Master Investor | Investing in the Age of Longevity](http://juvlabs.com/cdn/shop/files/Screen_Shot_2022-11-29_at_9.35.09_AM.png?v=1669732521&width=550)
November 17, 2022 | London
Our Chief Financial Officer, David Gill, and our Chief Science Officer, Martin Ducker, highlight the importance of aging as a risk factor of chronic diseases, and how Juvenescence taps into clinical and commercial opportunities.
![[Conference] Web Summit 2022 | Lisbon](http://juvlabs.com/cdn/shop/files/Image_46_copy.jpg?v=1667588424&width=550)
Dr. Greg Bailey hosted Web Summit's 2022 HealthConf track where industry giants, disruptive startups, investors & innovators gathered to redefine healthcare.
![[Interview] Voister Interviewed Dr. Greg Bailey at Web Summit 2022](http://juvlabs.com/cdn/shop/files/Screen_Shot_2022-11-04_at_5.47.25_PM.png?v=1667598457&width=550)
Through healthy habits and anti-aging drugs, we have every possibility of getting another 8-10 healthy years. Watch Greg's interview with Voister at Web Summit in Lisbon.
![[Conference] Master Investor Show 2022](http://juvlabs.com/cdn/shop/files/master_investor_show_2022-eventcard.png?v=1657539079&width=550)
Dr. Greg Bailey and Jim Mellon at Master Investor's flagship event for private investors, ‘The Master Investor Show’. This conference includes presentations from leading companies and experts within the financial and investment sectors.
![[Webinar] Investing in the Future of Longevity – the Ketone Chapter](http://juvlabs.com/cdn/shop/files/ketonewebinar-eventcard.png?v=1657539093&width=550)
Dr. Gregory Bailey, MD and Jim Mellon, co-founders of Juvenescence, brought together the leading experts in ketone metabolism and longevity to discuss new science regarding ketones, new investment opportunities, and an exciting, new Rx development initiative from Juvenescence.
![[Conference] Investing in the Age of Longevity 2021](http://juvlabs.com/cdn/shop/files/investing_in_the_age_of_longevity-eventcard.png?v=1657539110&width=550)
The lifespan revolution is coming – find out how to connect, collaborate and invest. Dr. Greg Bailey and Jim Mellon spoke about investment opportunities and the future of the industry.